- Comparison of the Infarct Size between the Loading of Ticagrelor and Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
-
Yun KH, Rhee SJ, Ko JS
- KMID: 2389603
- Korean Circ J.
- 2017 Sep;47(5):705-713.
- doi: 10.4070/kcj.2017.0044
BACKGROUND AND OBJECTIVES: Ticagrelor is considered a potent antiplatelet agent compared to clopidogrel. However, there are no studies regarding the effect of ticagrelor loading on infarct size in patients with... -
- CITED
-
- Close
- SHARE
-
- Close
- A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome
-
Lee JH, Ahn SG, Park B, Park SW, Kang YS, Lee JW, Youn YJ, Ahn MS, Kim JY, Yoo BS, Lee SH, Yoon J
- KMID: 2381560
- Korean J Intern Med.
- 2015 Sep;30(5):620-628.
- doi: 10.3904/kjim.2015.30.5.620
BACKGROUND/AIMS: Newer P2Y12 inhibitors, such as prasugrel and ticagrelor, have greater antiplatelet efficacy but may increase the risk of bleeding. In this study, we compared the pharmacodynamic efficacy of prasugrel... -
- CITED
-
- Close
- SHARE
-
- Close
- Adjunctive Cilostazol versus High Maintenance Dose of Clopidogrel in Patients with Hyporesponsiveness to Chronic Clopidogrel Therapy
-
Lee GY, Hahn JY, Lee SY, Kim HJ, Kim JH, Lee SY, Song YB, Choi SH, Choi JH, Gwon HC
- KMID: 1776915
- Yonsei Med J.
- 2013 Jan;54(1):34-40.
- doi: 10.3349/ymj.2013.54.1.34
PURPOSE: Whether addition of cilostazol is superior to increasing dose of clopidogrel in patients with hyporesponsiveness to chronic clopidogrel therapy is unknown. MATERIALS AND METHODS: We studied 73 patients with hyporesponsiveness... -
- CITED
-
- Close
- SHARE
-
- Close
- Determination of the Prevalence of Aspirin and Clopidogrel Resistances in Patients with Coronary Artery Disease by using Various Platelet-function Tests
-
Woo KS, Kim BR, Kim JE, Goh RY, Yu LH, Kim MH, Han JY
- KMID: 1022035
- Korean J Lab Med.
- 2010 Oct;30(5):460-468.
- doi: 10.3343/kjlm.2010.30.5.460
BACKGROUND: Dual therapy with aspirin and clopidogrel has emerged as the gold standard therapy for patients treated with drug-eluting stents (DES). However, there is variability in patients' responses to this... -
- CITED
-
- Close
- SHARE
-
- Close
